Prime Minister, Minister of Finance, Mr. Aïmene Benabderrahmane, chaired on Wednesday a government meeting, during which a draft law and executive decrees concerning the sectors of justice and the environment as well as the pharmaceutical industry were studied, according to a statement of the interests of the Prime Minister:
“Prime Minister, Minister of Finance, Mr. Aïmene Benabderrahmane, chaired this Wednesday 09 February 2022, a meeting of the government at the government palace. During its weekly meeting, the government considered the following points:
Justice sector:
A preliminary draft organic law setting out the procedures and modalities for notification and referral before the Constitutional Court was submitted.
This draft text comes within the framework of the application of the provisions of Article 196 of the Constitution of the first of November 2020, with the aim of enabling the Constitutional Court to exercise its powers and accomplish its task of extending constitutional control.
In accordance with the established procedures, the draft text will be studied at an upcoming meeting of the Council of ministers.
A draft executive decree amending and supplementing Executive Decree No. 06-198 of 31/05/2006, on the regulation applied to institutions categorised as Environmental Protection, has been submitted.
Since its promulgation in 2006, the implementation of the said Executive Decree has revealed a number of shortcomings and delays in the process of handing over exploitation permits.
In this regard, and in order to support and promote investment, while ensuring environmental protection, this text is to be amended to provide answers to the current context and persistent environmental accumulations, in particular by simplifying and easing procedures, expanding the scope of application of the decree to include mobile facilities, and defining the conditions for the settlement of existing classified enterprises.
Pharmaceutical production:
A draft executive decree on the code of good practice for the manufacture of pharmaceuticals for use in human medicine has been studied.
This project aims at defining the rules and conditions that pharmaceutical institutions must adhere to in order to establish a quality management system, ensuring the manufacture of pharmaceuticals intended for use in human medicine in accordance with international standards.
